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Abstract
Daptomycin is licensed in adults for the management of Staphylococcus aureus methicillin-resistant infections,
including bone and skin complicated infections. We describe for the first time its use in a renal transplant recipient
for Fabry-Anderson Disease with right heel osteomyelitis. The patient was unresponsive to first-line Teicoplanin and
second-line Tigecycline, whereas he was successfully treated with third-line Daptomycin monotherapy at 4 mg/Kg/
qd for 4 weeks. Local debridement was performed in advance of each line of treatment.
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Background
Vancomycin, the first-line antibiotic choice for bone and
joint infections caused by grampositive bacteria, has
been reported with declining rates of efficacy against
methicillin resistant Staphylococcus aureus (MRSA) iso-
lates [1]. The treatment of osteomyelitis, septic arthritis
and prosthetic joint infections with Vancomycin can
therefore be difficult, often requiring prolonged adminis-
tration [2-5]. The reduced susceptibility of S. aureus to
Vancomycin may be partially due to biofilms, facilitating
bacterial persistence [6-8]. Daptomycin, presently con-
sidered as a reliable alternative to the class of glycopep-
tides in these conditions [9], was recently used
successfully, alone or in combination, for osteomyelitis
caused by gram-positive pathogens including MRSA,
unresponsive to other antibiotics [10]. Dosing of Dapto-
mycin, however, and its ability to penetrate into
inflamed target tissues are still a matter of controversy
[11]. In this report we describe for the first time a case
of right hell osteomyelitis caused by MRSA and
successfully treated with third-line Daptomycin in a
renal transplant recipient for Fabry-Anderson Disease
(FAD).
Case presentation
A 38-year-old patient, diagnosed with FAD in 1990, was
put on hemodialysis since 1999 due to end-stage renal
insufficiency and received a kidney transplant in 2007.
Renal function did not recover immediately after renal
transplantation, and sequential renal biopsies documen-
ted early rejection. For this reason, the patient was put
on high dose oral Cyclosporine (150 mg twice daily) and
was treated with high dose steroids without benefit.
Everolimus (2.5 mg/daily) was therefore added and ster-
oids tapered. Renal function improved 4 months after
transplantation; hemodialysis was continued until that
time. Due to relapsing decreases in renal function after
each attempt to interrupt Everolimus, the association of
these drugs could not be stopped ever since, although
Cyclosporine could be reduced to 100 mg twice daily
after 1 year. Levels of both drugs were frequently moni-
tored, falling in the therapeutic range throughout fol-
low-up without further adjustments. Additional drugs
prescribed after transplantation were: Cardioaspirin, 100
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daily, Furosemide 25 mg/daily, Replagal
® (Agalsidase a)
3 times/weekly until hospitalization. During hemodialy-
sis, he suffered several traumatic and ischemic bone
lesions; a Dual-energy X-ray absorptiometry (DEXA)
scan, performed in 2006, revealed diffuse osteopenia, in
spite of intact parathyroid glands and normal parallel
parathormone levels.
In March, 2008, the patient was assisted in our ward
due to a large pulmonary infiltrate and treated with i.v.
Amoxicillin/Clavulanate and Fluconazole. The next
month he was hospitalized in the orthopedic ward of
Ortona Hospital (Chieti, Italy) because of an ulcerative
lesion at his right heel with redness, swelling and the
presence of necrotic tissue (Figure 1a). He was apyretic,
with normal white and red cell counts and near-normal
renal function tests, the estimated glomerular filtration
rate ranging between 56 and 83 mL/min/1.73 m
2 during
hospitalization, as calculated using the CKD-EPI for-
mula. Standard Rx scans of his right foot documented a
detachment of a wide fragment of his cortical spongiosa
in the lateral malleolus (Figure 1b). Cultural examina-
tion of wound essudates did not yield any isolate. The
patient underwent extensive debridement of necrotic tis-
sues and was put on hyperbaric oxygen therapy and Tei-
coplanin 200 mg i.v. for 4 weeks, without benefit. The
dose of Teicoplanin was decided by the assisting ortho-
pedists at that time, the fear of renal overload causing
Figure 1 a) Ulcerative lesion of the right heel; b) Standard Rx scan of the right heel at patient entry.
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evaluated in the Infectious Disease Unit of Pescara Gen-
eral Hospital for persistent fever and localized pain.
Inflammation indexes were remarkably altered. A sec-
ond debridement procedure was requested; cultures of
debris grew several Streptococcus agalactiae isolates. To
avoid renal overload, treatment with i.v. Tigecycline, 50
mg daily twice daily, together with Metronidazole, 500
mg three times daily, was prescribed. The patient was
still assisted at the orthopedic ward of Ortona Hospital
after consultation; a double daily access was arranged
for him as outpatient, and the prescription of Metroni-
dazole reduced to 500 mg twice daily. A slight local
improvement was noted, but relapsing fever ensued
after 30 days of treatment. ESR rose to 112 mm, CRP to
85 mg/L. A focused CT scan of his right heel confirmed
t h ep r e s e n c eo faf r a c t u r eo fh i sr i g h tc a l c a n e u sw i t h
fragmentation and irregular thickening of fracture edges,
tarsal bone loss, gaseous components in neighboring
soft tissues, abnormal spacing between calcaneus and
cuboid. A few days later, the patient underwent a third
debridement procedure. Culture specimens grew MRSA
isolates, sensitive to Vancomycin (MIC = 0.5 mg/L) and
Daptomycin. Based on these findings, i.v. Daptomycin (4
mg/kg daily) was started, and administered for 4 weeks.
CRP levels had dropped to 56 mg/L at this time. CPK
levels during treatment were frequently monitored and
found unmodified. At the end of treatment, deep palpa-
tion of the lesion did not cause pain; accompanying skin
lesions had resolved; liver and renal function tests were
normal, ESR was 50 mm and CRP 6,5 mg/L. Standard
Rx scans and focused control tomography of the heel
documented a reduction of bone resorption at affected
segments, indicating effective control of osteomyelitis
(Figure 2). The patient was discharged, and antibiotic
therapy was continued at home with oral Trimetoprim/
Sulfamethoxazole (1 double strength tablet twice daily)
and Doxycycline (100 mg twice daily) for 4 additional
weeks, with frequent monitoring of hematological para-
meters, immunosuppressant drugs and renal function
tests. No signs of toxicity were noted; the estimated
value of GFR ranged between 63 and 85 mL using the
CKD-EPI formula. At the end of treatment, the patient
could walk with the support of crutches. In February,
2009, a complete normalization of inflammation indices
was documented.
Discussion
Bone and joint discomfort is a common problem after
transplantation. It is now well known that skeletal
abnormalities, especially osteopenia with subsequent
fractures, may develop following kidney transplantation
[12,13], osteomyelitis being one of the complications of
fractures [14]. The complex impairment of bone
metabolism due to FAD and long lasting hemodialysis
in our patient may well have played a role in generating
his recalcitrant infection [15]. At our best knowledge,
here we report for the first time that Daptomycin in
monotherapy at low dose (4 mg/Kg/daily) was safe and
efficacious as a third line treatment for MRSA osteo-
myelitis of the heel in a renal transplant recipient on
long-term immune suppression with Cyclosporine and
Everolimus. Appropriate debridement of the lesion was
performed in this patient before each of his treatment
lines. No isolate was generated after the first procedure,
and Staphylococcus osteomyelitis was postulated as a
complication of his previous pneumonia. Vancomycin
sensitivity of S. aureus was preserved until recently [16];
Vancomycin, however, has poor bone penetration and
was unable to sterilize bone infections in animal models
[17,18]. In spite of recent reports on its efficacy in
human osteomyelitis at higher doses, the use of Vanco-
mycin in our transplanted patient with ensuing full dose
immunosuppressants was worrisome in the absence of a
microbiological isolate, as the high recommended trough
levels for Vancomycin (15-20 mg/L) in osteomyelitis
might indeed have harmed the renal graft [19]. Low
dose Teicoplanin was then preferred. Tigecycline plus
Metronidazole were chosen after the second debride-
ment because of the isolates of Streptococcus agalactiae
obtained at that time. The etiologic role of these bac-
teria, however, may be questioned also in view of treat-
ment failure. MRSA infection was finally documented by
specimens cultured at the third debridement procedure.
Monotherapy with Daptomycin for the following 4
weeks, at the cautious dose of 4 mg/Kg/daily, was pre-
ferred to Vancomycin. Long term administration of
Linezolid, which tested equally effective and could have
been given on an outpatient basis as oral therapy, was
reckoned as potentially associated with worrisome side
e f f e c t si nt h i sp a t i e n t ;f u r t h e r m o r e ,i ti sn o tp e r m i t t e d
for treatment over 21 days [20]. Daptomycin is presently
considered as an attractive alternative to glycopeptides
in these cases, because of its ability to penetrate into
inflamed subcutaneous adipose tissue and bones; in our
patient it induced a rapid bone and wound recovery,
with reversal of inflammation indexes [11]. The potency
of Daptomycin has been demonstrated against a wide
range of aerobic and anaerobic Gram-positive bacteria,
including MRSA, glycopeptide-intermediate S. aureus,
methicillin-resistant Coagulase-negative Staphylococci,
and Vancomycinresistant Enterococcus (VRE) in bactere-
mias and endocarditis [21,22], skin and skin structure
infection [23] and bone infections [10]. Daptomycin is
safe with any state of renal function and dosing guide-
lines are available for hemodialysis patients [24] as well
as for ICU patients with acute renal failure [25]. The
characteristics and outcomes of patients with
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doses ranging between 3.2 and 7.5 mg/Kg/daily (median
initial dose 5.6 mg/kg) were retrospectively evaluated in
the CORE 2004 database. Among clinically evaluable
patients with osteomyelitis, 63% were cured. In 48% of
them, Daptomycin was given concurrently with other
antimicrobial agents; MRSA accounted for 45% of the
identified pathogens. In another series, a 94% success
rate was observed in patients treated with Daptomycin
alone [26]. Although renal transplant recipients are
most intensely immunosuppressed early in the post-
transplantation period, immunosuppressive therapy
c o u l dn o tb et a p e r e di no u rp a t i e n to v e rt h ep a s t3
years and during treatment. Therefore, the efficacy of
Daptomycin, in conjunction with the repeated local deb-
ridement, may have played a major role.
Conclusions
Our experience adds to the large body of evidence that
Daptomycin is effective and does not carry a relevant
risk of renal damage in fragile patients as those with
impaired renal function, renal transplant recipients or
patients on nephrotoxic drugs. It could be effectively
and safely used for MRSA osteomyelitis in a renal trans-
plant recipient with recovered renal function. Higher
dosing at 6 to 8 mg/kg/daily should be cautiously tested
in the event of life-threatening infections, with tight
monitoring of ensuing nephrotoxicity due to immuno-
suppressive agents [27,28].
Consent
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Figure 2 Standard Rx scan of the right heel at end of treatment.
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